A phase three trial has found that a personalised vaccine, used alongside existing immunotherapy, helps prevent melanoma from returning after surgery. By using mRNA technology to target individual tumour DNA, this approach offers a new method for managing high-risk cancer patients - a development that researchers are describing as a significant step forward in clinical treatment.